Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

17.78
+0.48002.77%
Volume:3.88M
Turnover:69.04M
Market Cap:14.18B
PE:-15.91
High:18.10
Open:17.73
Low:17.42
Close:17.30
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.85
T/O Rate:2.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:22.51
PE(LYR):-12.31

Loading ...

Summit: Akeso reports ‘positive’ results from Phase III HARMONi-GI11 study

TIPRANKS
·
Aug 26

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

THOMSON REUTERS
·
Aug 26

Summit Therapeutics - Study Meets Key Secondary Endpoints of Pfs and Orr

THOMSON REUTERS
·
Aug 26

Summit Says FDA Sets Nov. 14, 2026 Action Date for Ivonescimab Lung Cancer Filing

Reuters
·
Aug 25

Summit Therapeutics falls -8.5%

TIPRANKS
·
Aug 17

EV targets set to be watered down

cityam
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)

TIPRANKS
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Summit Partner Akeso Wins China NMPA Approval for Ivonescimab-Chemo in First-Line Squamous NSCLC

Reuters
·
Aug 12

Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo

Reuters
·
Aug 12

Ivonescimab in Combination with Chemotherapy Approved in China by Nmpa for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Aug 12

Summit Therapeutics Inc. : Leerink Partners Raises to Market Perform from Underperform; Raises Target Price to $13 from $12

THOMSON REUTERS
·
Aug 12

China's Automakers Capture Three Spots in UK July Best-Selling Top Ten

Deep News
·
Aug 06

Barclays Remains a Hold on Summit Therapeutics (SMMT)

TIPRANKS
·
Aug 06

Summit announces expansion of development program for ivonescimab

TIPRANKS
·
Aug 05

Summit Therapeutics - Initiates Global Phase Ii/Iii Harmoni-Gu1 Trial of Ivonescimab in Bladder Cancer

THOMSON REUTERS
·
Aug 05

Miliband refused to meet motor trade body to discuss zero emissions mandate

cityam
·
Jul 30

Vehicle production drops in first half of year

cityam
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)

TIPRANKS
·
Jul 29

Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)

TIPRANKS
·
Jul 27